Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-1.21 Insider Own3.10% Shs Outstand22.02M Perf Week4.57%
Market Cap897.32M Forward P/E- EPS next Y-2.52 Insider Trans- Shs Float22.02M Perf Month40.42%
Income-27.10M PEG- EPS next Q-1.13 Inst Own45.30% Short Float4.19% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio4.90 Perf Half Y-
Book/sh42.02 P/B0.97 EPS next Y59.10% ROA- Target Price46.00 Perf Year-
Cash/sh7.04 P/C5.79 EPS next 5Y- ROE- 52W Range26.51 - 44.01 Perf YTD30.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.92% Beta-
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low52.87% ATR3.22
Employees34 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.24% 10.53%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.84 Prev Close40.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume188.48K Price40.53
Recom1.50 SMA2010.71% SMA5022.80% SMA20022.80% Volume152,965 Change-0.55%
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Aug-09-18 08:00AM  AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-08-18 08:00AM  AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-16-18 10:52AM  Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls Benzinga
Jun-27-18 08:00AM  AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors GlobeNewswire
Jun-25-18 04:30PM  AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option GlobeNewswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:42PM  AVROBIO, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.